Tsontcho Ianchulev

Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study

David M. Brown, Mark Michels, Peter K. Kaiser et al. · Ophthalmology · 2008 · 1.3K citations

Ocular Disease, Ophthalmology, Two-year Results +5

Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1

Carl D. Regillo, David M. Brown, Prema Abraham et al. · American Journal of Ophthalmology · 2008 · 859 citations

Ocular Disease, Ophthalmology, Experimental Ophthalmology +4

A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration

David S. Boyer, Jeffrey S. Heier, David M. Brown et al. · Ophthalmology · 2009 · 344 citations

Ocular Disease, Experimental Ophthalmology, Ophthalmology +3

Two-Year COMPASS Trial Results: Supraciliary Microstenting with Phacoemulsification in Patients with Open-Angle Glaucoma and Cataracts

Steven D. Vold, Iqbal Ike K. Ahmed, E. Randy Craven et al. · Ophthalmology · 2016 · 267 citations

Open-angle Glaucoma, Ophthalmic Surgery, Vitreous Body +6

ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: TWO-YEAR RESULTS OF THE ANCHOR STUDY

Diane Brown, Mark Michels, Peter K. Kaiser et al. · 2009 · 165 citations

Anchor Study Group, Ocular Disease, Ophthalmology +6